Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, Storm TA, Schubert S, Hutter G, Narayanan C, Chu P, Raabe EH, Harsh G 4th, Taylor MD, Monje M, Cho YJ, Majeti R, Volkmer JP, Fisher PG, Grant G, Steinberg GK, Vogel H, Edwards M, Weissman IL, Cheshier SH (2017) Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med 9(381):eaaf2968. doi: 10.1126/scitranslmed.aaf2968 PMID: 28298418
Summary: A humanized anti-CD47 antibody has proven to be an effective treatment for malignant pediatric brain tumors by disrupting the CD47-SIRPα anti-phagocytic axis. This breakthrough therapy shows promise in improving outcomes for young patients with these challenging tumors.